Extended indication Pediatric Psoriasis 6-12 jr
Therapeutic value Possible added value
Total cost 1,600,000.00
Registration phase Clinical trials

Product

Active substance Ustekinumab
Domain Chronic immune diseases
Main indication Skin diseases
Extended indication Pediatric Psoriasis 6-12 jr
Proprietary name Stelara
Manufacturer Janssen
Route of administration Subcutaneous
Therapeutical formulation Injection
Budgetting framework Intermural (MSZ)
Additional remarks IL12/23 remmer

Registration

Particularity Indication extension
Expected Registration July 2020
Orphan drug No
Registration phase Clinical trials

Therapeutic value

Therapeutic value Possible added value
Substantiation Ten opzichte van TNF remmers
Duration of treatment continuous
Frequency of administration 5 times a year
Dosage per administration 0,75 mg/kg
References NCT02698475

Expected patient volume per year

Patient volume

< 100

Market share is generally not included unless otherwise stated.

Additional remarks De inschatting van de werkgroep is dat er maximaal 100 patiënten zijn die voor deze indicatie van ustekinumab in aanmerking komen.

Expected cost per patient per year

Cost 16,000.00
References Medicijnkosten.nl
Additional remarks 45 mg wegwerpspuit kost €3.235,84. Voor de behandeling van een patiënt van 50 kg betekent dit 5 spuiten per jaar en dus €16.179,20

Potential total cost per year

Total cost

1,600,000.00

This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year.

Off label use

Off label use No

Indication extension

Indication extension Yes
Indication extensions Lupus

Other information

There is currently no futher information available.